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Abstract
Integrating signals from the extracellular matrix through the cell surface into the nucleus is an essential feature of
metazoan life. To date, many signal transducers known as shuttle proteins have been identified to act as both a
cytoskeletal and a signaling protein. Among them, the most prominent representatives are zyxin and lipoma pre-
ferred (translocation) partner (LPP). These proteins belong to the LIM domain protein family and are associated
with cell migration, proliferation, and transcription. LPP was first identified in benign human lipomas and was sub-
sequently found to be overexpressed in human malignancies such as lung carcinoma, soft tissue sarcoma, and leu-
kemia. This review portrays LPP in the context of human neoplasia based on a study of the literature to define its
important role as a novel protooncogene in carcinogenesis.
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Genetic Background
Specialized cell adhesion sites not only play a role in the architectural
organization and polarity of the cell but also are dynamic units di-
rectly involved in communicational processes. Adhesion receptors
and their cytoskeletal partners can regulate nucleocytoplasmatic traf-
ficking of signaling proteins and are thereby capable of influencing
gene expression [1–4]. One such protein that may be involved in this
process is the LIM-containing protein LPP (lipoma preferred (trans-
location) partner) [1].
Petit et al. [5] initially described LPP as the preferred translocation
partner in a cytogenetic subgroup of lipomas that is characterized by
translocations that mainly involve chromosome 12. Several chromo-
somes were identified as translocation partners of chromosome 12
with 3q27-q28 being preferentially involved. Moreover, it was shown
that the high-mobility group (HMG) protein gene HMGA2 at
12q15 is consistently rearranged as a consequence of these translo-
cations. Fusion transcript analysis of HMGA2 in the lipoma cell line
Li-501/SV40 unmasked ectopic genetic sequences that originated
from the chromosome segment 3q27-q28. These results subsequently
yielded in the identification and characterization of the chromosome 3
translocation partner gene named lipoma preferred (translocation)
partner (LPP) gene. Northern blot analysis detected a messenger
RNA (mRNA) of more than 10 kb in a variety of human tissues
[5,6]. The gene was found to span a genomic region of more than
400 kb. Detailed sequencing analysis of LPP revealed an open read-
ing frame of 1836 nucleotides. The main promoter of the LPP gene
is located in intron 2 leading to a full-length LPP protein of a highly
modular organization [5]. An alternative promoter was found in
murine intron 7 leading to a short form of LPP specifically expressed
in testis [7]. Alternative LPP variants are also assumed to exist in hu-
man because high levels of two smaller LPP gene transcripts have also
been detected specifically in the testis [5]. However, these smaller hu-
man LPP transcripts have not been characterized in all detail yet.
Functional Organization, Structure, and Binding
Partners of LPP
LPP encodes an 80-kDa protein that was characterized as a novel
member of group 3 proteins in the LIM family [5]. On the basis of
the arrangement, position, and high sequence similarity of the LIM
domains of LPP with those of zyxin, LPP was classified as a zyxin
family member. This protein family consists of zyxin, ajuba, LIMD1,
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thyroid receptor–interacting protein 6 (TRIP6, also termed as zyxin-
related protein 1), WT1-interacting protein, migfilin, and LPP [8–14],
all of which are strongly involved in cellular motility, proliferation,
and tumorigenesis [12,13,15,16].
The LPP gene encodes a proline-rich protein containing a leucine
zipper motif in its amino-terminal region and three LIM domains at
the carboxy-terminal end (Figure 1) [5]. LIM domains are cysteine-
and histidine-rich domains that form two zinc fingers capable of
mediating protein-protein interactions. Through binding to other
partners, LIM proteins participate in diverse cellular processes [17,18].
LPP mRNA is ubiquitously expressed in virtually all types of tis-
sues with emphasis on organs of the reproductive tract [19,20]. In
contrast to the ubiquitous LPP mRNA presence, the protein is selec-
tively expressed in smooth muscle cells (SMCs), especially in the
uterus, stomach, corpus cavernosum, portal vein, aorta, bladder, and
ileum [21].
LPP not only is colocalized with vinculin at sites of cell adhesion
but also translocalizes into the nucleus [1]. In various benign and
malignant tumors, a mutant form of LPP is permanently present
in the nucleus [22,23]. Considering the size of LPP, it is unlikely that
the protein translocates into the nucleus by mass action and free dif-
fusion. Thus, an active and selective import mechanism seems to be
more likely [1,21,22,24].
All three LIM domains of LPP cooperate to provide robust target-
ing to focal adhesions, with the linker region between LIM domains 1
and 2 playing a pivotal role. Overexpression of the LIM domains
results in the depletion of endogenous LPP and vinculin from focal
adhesions [1]. Thus, the C-terminal LIM domains of LPP are re-
quired for targeting the protein to points of cell-cell and cell-matrix
contacts. In contrast, the LIM domains are dispensable for nuclear
LPP localization [1]. Beyond its structural function, the C-terminal
LIM domains 2 and 3 exhibit transcriptional activity by enhancing
transcription factors [25].
The proline-rich pre-LIM region of LPP harbors an intrinsic nu-
clear export signal [1,22,26] and contains binding sites for α-actinin,
vasodilator-stimulated phosphoprotein (VASP), and LIM and SH3
domain protein 1 (LASP-1) [5,26,27]. LPP and its family member
zyxin differ in their absolute and functional relevant number of their
VASP binding repeats (FPPPPP repeats). Whereas LPP harbors two
proline-rich motifs, of which only one binds VASP in vitro [22], zyxin
features four functional active FPPPPP repeats [28–30].
VASP has been proposed to increase actin polymerization and
force cell protrusion. By binding to the proline-rich repeats of LPP
and zyxin, VASP is recruited to specific cellular locations, thus direct-
ing changes in actin dynamics [30]. The LIM region of zyxin and
LPP acts as a negative autoregulatory domain that normally masks
the VASP-recruiting function of the FPPPPP repeats, thereby pre-
venting VASP incorporation into actin networks [31].
Similar to zyxin, LPP was found to bind to α-actinin in vitro and
in vivo [26,32]. Studies using the three-hybrid system indicated that
zyxin and LPP compete for the same binding site in the central rod of
α-actinin containing spectrin-like repeats 2 and 3. On the LPP site, a
conserved motif present at the N-terminus is involved in the inter-
action with α-actinin. Quantitative data obtained with the two- and
three-hybrid systems suggested that LPP has a lower affinity for
α-actinin than zyxin does. It is likely that this difference leads to
slightly variant roles played by LPP and zyxin during the assembly
and disassembly of focal adhesions [26].
Although both proteins localize at cell adhesions, zyxin is more prom-
inently distributed along stress fibers. Moreover, there is a difference in
the relative abundance of the two proteins. In fibroblasts, the level of
zyxin is approximately five times higher than that of LPP, whereas epi-
thelial cells show no significant difference in zyxin/LPP protein levels
[22]. Despite the high sequence homology of zyxin and LPP, the ob-
served differences in localization and affinity for the same binding part-
ners might be due to the minor variants in their amino acid sequences.
Recently, it was demonstrated that, LPP-VASP binding is required
for anchoring α-actinin at cell-cell contacts, whereas zyxin localiza-
tion and function at cell-cell contacts is independent of the α-actinin
binding site [32], leading to the assumption that zyxin is recruited to
cell-cell contacts by other docking proteins, e.g., LASP-1 [33,34].
With its C-terminal tail, LPP interacts directly with the tumor-
suppressor Scrib. Interestingly, although all zyxin family members
share high sequence homology, only LPP and TRIP6 bind to Scrib
[24]. LPP/Scrib will be discussed in more detail later.
Using the C-terminus of LPP as bait in a yeast two-hybrid system,
another interaction partner of LPP and a key player in focal adhe-
sion organization was identified— palladin. The palladin-interacting
Figure 1. Schematic illustration of the LPP gene (upper part) and LPP protein (lower part). LPP spans over a genomic region of >400 kb.
The gene product consists of 612 amino acids. Several binding sites for other proteins are located within the N-terminal pre-LIM region:
the first of two LPP/TRIP6 similar regions (SR1) followed by binding motifs for α-actinin (αA), VASP (V), a nuclear export signal (N), the
second LPP/TRIP6 similar region (SR2), and a zyxin/LPP/TRIP6/LIMD1 similar region (SR3). The LIM domain region consists of three
tandem LIM domains, each of which is equipped with a double zinc finger structure. The Scrib-binding motif (S) is located at the very
C-terminal tail of LPP.
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region of LPP was mapped to the first and second LIM domains,
whereas the N-terminus of palladin interacts with LPP, both in vitro
and in vivo. Like LPP, palladin is highly expressed in differentiated
smooth muscle (SM) and localized at focal adhesions, at isolated
lamellipodia, and at dense bodies [35]. Both LPP and palladin en-
hance cell migration and spreading [36], and their expression is
markedly decreased in migration-defective focal adhesion kinase
(FAK)–null cells [21,37].
Recently, LPP was identified as a substrate of the protein-tyrosine-
phosphatase 1B, a negative regulator of multiple signaling pathways
downstream of receptor tyrosine kinases and functionally linked to
Ras signaling [38,39].
The modular organization of LPP and its multiple interaction sites
for cytoskeletal proteins suggest an important role in focal adhesion
architecture as a versatile scaffolding and adaptor protein.
An overview of the putative functions and binding partners of LPP
is given in Tables 1 and 2, respectively.
LPP and Its Effect on Gene Transcription
LPP has been shown to shuttle into the nucleus and to possess a
Crm1-dependent nuclear export signal. The protein exhibits two do-
mains harboring transcriptional activation capacity that coincides
with the LIM domains and the proline-rich region of the LPP pro-
tein [1,22]. Within the nucleus, LPP is recruited to PEA3-dependent
promoter regions and acts as a coregulatory protein enhancing the
transactivational potential of PEA3 [40]. PEA3-binding sites have
been identified in the regulatory regions of many genes associated
with tumorigenesis as well as embryogenesis. A significant fraction
of target genes encodes proteases required for degradation of the ex-
tracellular matrix (ECM), for example, serine proteases, urokinase
plasminogen activator, COX-2, and several matrix metalloproteinases
(MMPs) [41,42].
In a recent article, vascular endothelial growth factor was also iden-
tified as a potential PEA3 target gene [43]. Matrix metalloproteinases
in turn contribute to metastatic dissemination of tumor cells by de-
grading the ECM, and their deregulated expression has been associ-
ated with the capability of tumor cells to metastasize [41,44,45].
LPP was shown to substantially increase the reporter gene activity
of the target gene COX-2 in a dose-dependent manner when cotrans-
fected with PEA3 and mitogen-activated kinase/ERK kinase [40].
However, the role of the mitogen-activated protein kinase (MAPK)
pathway in controlling the activity of the PEA3-LPP complex is still
under investigation.
LPP also interacts with the related ETS transcription factor ER81 by
enhancing its transactivational potential [40]. Like PEA3, ER81 has
been shown to play an important role in breast tumor metastasis as well
as human epidermal growth factor receptor 2/neu–mediated mammary
oncogenesis [46]. In contrast, less effect of LPP is seen on the third
Table 1. Overview of the Putative LPP Functions in the Context of Intracellular LPP Localization.
Location Function Reference(s)
Focal contacts/cell-cell contacts Modulation of cytoskeleton and linker between membrane and cytoskeleton [21,37]
Scaffolding and adaptor protein [26]
SMC migration [21,37]
Interaction partner for VASP, zyxin, palladin, Scrib, α-actinin, and LASP-1 [24,26,27,30,32,35,51]
Recruitment of VASP to cell-cell adhesions [30,32]
Nucleus Independent transcription factor [1,22,25,51]
Transcriptional coactivator of transcription factors such as PEA3 and ER81 [25,40]
Table 2. LPP Binding Partners and Their Putative Roles in Human Cancer.
Protein Expression Localization Putative Physiological Function Putative Role in Human Cancer Reference(s)
LASP-1 Ubiquitous cc, fa, nuc scaffolding protein, zyxin-recruitment to fa and cc, NCST Overexpression in breast, ovarian and liver cancer increases
motility and proliferation and is associated with metastasis
[33,34,90–95]
VASP Ubiquitous cc and fa Regulation of actin polymerization, involved in
cellular migration
Overexpression in lung cancer is positively correlated with
grading and staging
[96–100]
Overexpression in breast cancer cells enhances migration
Palladin Ubiquitous cc, fa, Z-discs Actin organization, involved in cell motility, embryonic
development, scar formation in the skin,
neuronal development
Palladin mutation causes familial pancreatic cancer [101–105]
Overexpression is found in spontaneous pancreatic cancer
Overexpression in breast cancer cells enhances migration
Scrib Ubiquitous cc, fa, cy Tumor suppressor; essential for cell shape, polarity, and
directed cell migration in early embryonic development
Deregulation leads to breast cancer formation [51,106–109]
Invasive cervical carcinomas show decrease in Scrib due to
ubiquitin-mediated degradation by the high-risk papilloma
virus E6 proteins
Scrib is downregulated in colon cancer
PEA3 Epithelia nuc ETS transcription factor regulated by Ras and
MAPK pathway
Transcription of prometastatic genes such as serine proteases,
urokinase plasminogen activator, COX-2, and several MMPs
in various cancers
[40–44,110]
ER81 Mesenchyme nuc Related ETS transcription factor of the PEA3 group Role in breast tumor metastasis as well as HER-2/neu–mediated
mammary oncogenesis
[40,44–46]
α-actinin Ubiquitous cc, fa, F-actin Scaffolding protein in fa and cc, recruitment of LPP and
other signaling proteins involved in cellular motility,
actin filament cross-linking, links cytoskeleton to
transmembrane proteins
Overexpression of α-actinin isoforms is associated with worse
prognosis of patients with astrocytomas, ovarian, breast, lung
colorectal, and esophageal cancers
[32,111–115]
Z-discs, stress-fibers
All LPP binding partners are dysregulated in various cancer entities. Many of them contribute to tumor invasiveness and migration.
cc indicates cell-cell contact; cy, cytoplasm; fa, focal adhesion; NCST, nucleocytoplasmatic signal transduction; nuc, nucleus.
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member of this subfamily, ets-related molecule, suggesting a specificity
of action [40]. However, the knowledge about the effects of ER81 and
its target genes in the context of LPP coactivation is fragmentary.
Recent work has shown that LPP can also act as an indepen-
dent transcription factor with or without binding to other transcrip-
tion factors. Moreover, HMGA2/LPP fusion proteins (see also LPP
Fusion Genes section) retain the transactivational functions of the
LPP LIM domains and thus function as genuine transcription fac-
tors [25,47,48].
LPP in Early Embryonic Development
LPP is localized at focal adhesions and cell-cell contacts and is in-
volved in the regulation of SMC migration [49]. A known interaction
partner of LPP in human is the tumor suppressor protein Scrib [11,24].
Knockdown of Scrib expression during zebrafish embryonic devel-
opment results in defects of convergence and extension (C&E)
movements, which appear during gastrulation and cause elongation
of the anterior-posterior body axis. During vertebrate gastrulation
and neurulation, C&E reflects the medial migration and intercala-
tion of mesodermal and neuroectodermal cells. The mediolateral cell
polarization mediated through C&E is controlled by the noncanoni-
cal wingless (Wnt) signaling pathway, which represents the vertebrate
planar cell polarity pathway [50–52].
Interestingly, silencing of LPP in zebrafish embryos also results in
impaired C&E movements, phenocopying noncanonical wingless-
type MMTV integration site family member 11 (Wnt11) signaling
mutants. The defective dorsal convergence movements are associated
with a reduced ability of embryonic cells to migrate along straight
paths, affecting both mesodermal and neuroectodermal structures.
The embryos with decreased LPP expression showed a shortened
body axis, a phenotype also observed for other genes involved in
gastrulation [51,53,54]. Furthermore, the expression of LPP is signifi-
cantly reduced in embryos with morpholino-mediated knockdown
of Wnt11 and in embryos overexpressing Wnt11 or a dominant-
negative form of Rho kinase 2 (ROK-2), a downstream effector of
Wnt11. These data suggest that LPP expression is dependent on non-
canonical Wnt signaling and that LPP acts downstream of Wnt11 and
ROK-2 [51]. Likewise, an involvement of LPP in ROK-dependent sig-
naling pathways was demonstrated in human iliac vein SMCs [37].
Surprisingly, Lpp knockout mice do not present defects of C&E
during embryonic development. Moreover, Lpp−/− mice show no in-
creased mortality compared with wild-type littermates and reach
adulthood without displaying any obvious abnormalities [7]. This
could be in part explained by the functional redundancy of zyxin family
proteins because zyxin knockout mice also lack any macroscopic
abnormalities [55]. However, Scrib and α-actinin mRNA levels were
significantly reduced in Lpp−/− mice. In addition, Lpp−/− murine em-
bryonic fibroblasts show reduced migration capacity and viability [7].
LPP in SM Physiology
Little is known about the physiological role of LPP and its opera-
tions to ensure normal protein signaling, but to date, LPP is best
studied in SMCs [21,36,37,49,56].
Immunofluorescence microscopy demonstrated the almost selec-
tive expression of LPP in vascular and visceral SMC [21,37]. Con-
sistently, single nucleotide polymorphisms in the LPP gene are
associated with severe villus atrophy of the small intestine in celiac
disease [57]. LPP has also been detected among a core of compu-
tationally predicted SM-specific genes from expressed sequence tag
data [58] supporting the idea of LPP as a novel marker for SMC dif-
ferentiation [37].
In other mature (noncultured) tissues, including heart and skeletal
muscle, the protein is barely present, and its concentration correlates
with the levels of the SM marker α-actin. LPP is present at 100-fold
higher protein level in SM-rich tissues, including bladder, uterus,
ileum, and aorta, than in non-SM organs, such as liver, heart, or
brain. In healthy SM tissues, Gorenne et al. [21] reported detection
of LPP in punctate foci at the cell surface where it colocalized with
vinculin in peripheral membrane-dense bodies involved in actin fila-
ment attachment sites. Overexpression of LPP increased epidermal
growth factor–stimulated migration of vascular SMCs, suggesting the
participation of LPP in cell motility [21]. Conversely, LPP knockout
led to reduced migration of murine embryonic fibroblasts [7].
trans-Retinoic acid treatment of A404 cells was shown to signifi-
cantly increase LPP levels as well as SM α-actin, myosin heavy chain
and smoothelin mRNA levels in a ROK-dependent manner. Treat-
ment with the ROK inhibitor Y-27632 led to dissociated focal adhe-
sions as well as reduced LPP staining at the cell periphery. Moreover,
enhanced nuclear accumulation of LPP is observed after cell incuba-
tion with nuclear export inhibitor leptomycin B [37]. Similarly, treat-
ment of human iliac vein SMCs (HIVS) with leptomycin B caused
accumulation of LPP in the nucleus [21]. Therefore, LPP apparently
has a potential for relocating to the nucleus through a shuttling mecha-
nism that is sensitive to inhibition of ROK. Cytoplasmic-nuclear
shuttling has also been demonstrated for zyxin [59] and TRIP6 [60],
suggesting this as a common property for the group 3 LIM proteins.
Thus, it is intriguing to consider a possible signaling role for LPP
in SMCs, possibly in the transcriptional feedback control of cytoskele-
tal proteins.
In adult pig hearts, intact coronary arteries exhibit strong immu-
nostaining for LPP that colocalized with SM α-actin and smoothelin
in the tunica media. In contrast, no expression of LPP was found in
the adventitial layer. In injured vessels 28 days after stent implanta-
tion, neointimal cells migrating around the stent lesion were positive
for LPP and SM α-actin but not for smoothelin [37]. Adventitial
cells remained negative, whereas LPP expression could be detected
in the walls of microvessels located in the adventitial layer [37]. Sim-
ilar findings were reported for remodeling of injured rat aortic ar-
teries [36]. These dynamic expression patterns in injured arteries
suggest that LPP may act in concert with multiple players to facilitate
cytoskeletal remodeling events needed to accomplish the transition
from stationary to migrating SMCs in vivo [36,49,56].
Overexpression of myocardin, a well-known cofactor of the serum
response factor (SRF) [61], significantly increased LPP mRNA ex-
pression in A404 cells [37]. Interestingly, inactivation of RhoA de-
creased myocardin mRNA expression in retinoic acid–treated A404
cells and HIVS. In addition, LPP silencing significantly decreased
SMC migration. LPP expression was also markedly reduced in
FAK-null cells known to show impaired migration [36]. Consistently,
overexpression of LPP in cultured HIVS increased epidermal growth
factor–stimulated cell migration by approximately 2.5-fold in a trans-
well chemotaxis assay. Moreover, expression of LPP in migration-
defective FAK-null cells led to a significant increase in cell spreading on
a fibronectin matrix. This is in agreement with data demonstrating an
up-regulation of LPP in FAK −/− cells with restored FAK expression [36].
These results suggest that levels of LPP in SMCs are controlled by
FAK signaling and raise questions about the role of FAK and LPP as
determinants of SMC phenotype [21,37].
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Recently, Gorenne et al. [37] reported the LPP gene being respon-
sive to RhoA-mediated signaling pathways that activate myocardin-
dependent transcription in SMC differentiation. In an extending
work, Petit et al. [62] focused on the transcriptional regulation of
the LPP gene by myocardin. The murine LPP gene contains three
evolutionarily conserved CArG boxes. One box is part of an alter-
native promoter in intron 2. Petit et al. [62] showed that this pro-
moter is directly regulated by SRF and myocardin, which thereby
modulate transcription of LPP in SMC. Overexpression of myo-
cardin resulted in an approximately three-fold increase of porcine
LPP gene expression after 48 hours [37]. Thus, LPP was classified
as a novel myocardin/SRF target gene [37,62]. In conclusion, LPP
seems to be a SRF/myocardin– and RhoA/ROK–dependent SMC
differentiation marker that plays a role in regulating SMC migra-
tion [21,37,62].
LPP in Tumorigenesis and Cancer
After the discovery of LPP in lipoma, many other human tumors
have been identified, which take advantage of the physiological LPP
properties to increase their malignant potential. To date, three dif-
ferent strategies have been identified, which allow tumors to usurp
the physiological LPP signaling mechanism to enhance their run-
away proliferation:
A) Formation of oncogenic LPP fusion genes
B) Overexpression of LPP leading to the disruption of the nor-
mal LPP signaling pathway
C) Abuse of the LPP shuttle mechanism for oncogenic signaling
to the nucleus
A) LPP Fusion Genes
LPP is a frequent fusion partner for several oncogenes. The most
prominent genes are members of the “high mobility group AT hook”
HMGA protein family consisting of four proteins: HMGA1a,
HMGA1b, HMGA1c, and HMGA2. All are nuclear factors charac-
terized by three DNA-binding domains, called AT hooks, and an
acidic carboxy-terminal tail. The proteins are architectural transcrip-
tion factors that both positively and negatively regulate the transcrip-
tion of a variety of genes [63–66], thereby influencing a considerable
number of cellular processes including cell growth, proliferation, dif-
ferentiation, and apoptosis. HMGAs do not directly activate tran-
scription but rather regulate gene expression by changing DNA
conformation [63].
Both HMGA1 and HMGA2 are barely detectable in normal adult
tissue but are abundantly and ubiquitously expressed during embryo-
nic development [63,65,66]. In malignant epithelial tumors as well
as in leukemia, however, expression of HMGA1 is again strongly up-
regulated to embryonic levels, thus leading to ectopic expression of
(fetal) target genes. HMGA2 overexpression has a causal role in in-
ducing neoplasia and a malignant phenotype [5,63,67].
HMGA genes are often involved in chromosomal rearrangements.
Such translocations are mostly detected in benign tumors of mesen-
chymal origin and are believed to be one of the most common chro-
mosomal rearrangements in human neoplasia [63,68–70]. In most
cases, HMGA2 alterations involve breaks within the third intron
of the gene resulting in aberrant transcripts carrying exons 1 to 3,
which encode the three DNA-binding domains, fused to ectopic
sequences [64].
The LPP gene is the most frequent translocation partner ofHMGA2
in a subgroup of lipomas. Moreover, LPP is also frequently rearranged
in cases without cytogenetic detectable involvement of 3q27-q28. To
date, two alternative HMGA2/LPP hybrid transcripts have been char-
acterized. These two transcripts differ in the number of either two or
three LIM domains in the predicted HMGA2/LPP fusion protein
[71–73] (Figures 2 and 3, A and B). Interestingly, both forms are
expressed only in the nucleus [22]. A truncated form of HMGA2
carrying the three DNA-binding domains of HMGA2 and the
LIM domains of the LPP gene caused malignant transformation of
NIH3T3 cells, whereas the wild-type HMGA2 does not exert any
transforming activity [67]. These findings indicate that, specifically,
the fusion of HMGA2 together with LPP achieves oncogenic poten-
tial [22,67].
TheHMGA2/LPP fusion protein activates transcription through the
well-characterized PRDII element, which is a part of the interferon-β
(IFN-β) enhancer and known to bind to HMGA2. It was also shown
thatHMGA2/LPPactivates transcription through theHLA-B associated
transcript 1 element of the rhodopsin promoter, an HMGA1-binding
element. Finally, in a number of lipomas, HMGA2/LPP and HMGA2
are coexpressed with wild-type HMGA2 even augmenting the trans-
activational functions of ectopic HMGA2/LPP. These results support
the concept that the transactivational functions of the novel HMGA2/
LPP transcription factor contribute to lipomagenesis [25,64,74].
Recent work showed that transforming growth factor β (TGF-β)–
induced expression of HMGA2 was associated with the development of
epithelial-mesenchymal-transition (EMT) [75]. Epithelial-mesenchymal-
transition occurs during embryogenesis, carcinoma invasiveness, and
metastatic dissemination and can be regulated by TGF-β signal-
ing through intracellular Smad transducers. The specific molecular
mechanisms that control the initiation of EMTare, to date, widely un-
known. Transcriptomic analysis, however, revealed that the Smad path-
way induces the HMGA2 gene during EMT. Endogenous HMGA2
mediates EMT by TGF-β, whereas ectopic HMGA2 causes irrevers-
ible EMT characterized by severe E-cadherin suppression. HMGA2
controls the expression of four known regulators of EMT, the zinc-
finger proteins Snail and Slug, the basic helix-loop-helix protein Twist,
and inhibitor of differentiation 2 [75]. Thus, ectopic overexpression of
a hybrid HMGA2/LPP gene possibly provides a mechanistic explana-
tion for a disruption of the physiological HMGA2 pathway resulting
in tumor development.
The existence of identical fusion genes in different types of tumors
is a very common strategy of these cells to promote proliferation.
Consistently, HMGA2/LPP fusion transcripts have been reported
in lipoma, pulmonary chondroid hamartoma (PHC), and soft tissue
chondroma [47,48,71–73,76–78]. The high frequency of t(3q27-
28;12q14-15) in lipomas and PCHs renders the HMGA2/LPP fusion
gene the most common fusion gene in human tumors [77,79]. All
tumors characterized by this HMGA2/LPP gene product share the
same structure, that is, a protein composed of the AT hooks of
HMGA2 and the LIM domains of LPP. Its common occurrence in
PCHs indicates the absence of a larger deletion of the LPP locus ac-
companying the translocation [79,80], as described in a lipoma
[73,74]. Moreover, in primary central nervous system lymphomas
(PCNSLs, diffuse large B-cell lymphomas confined to the brain),
LPP was fused to the BCL6 gene [81]. BCL6 is a protooncogene
encoding a nuclear transcriptional repressor, with pivotal roles in ger-
minal center formation and regulation of lymphocyte function, dif-
ferentiation, and survival. BCL6 suppresses p53 in germinal center B
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cells and its constitutive expression can protect B-cell lines from
apoptosis induced by DNA damage [82]. Little is known about chro-
mosomal aberrations underlying PCNSLs. However, fluorescence
in situ hybridization analysis of 41 PCNSLs revealed that 14 tumors
(34%) carried a breakpoint in the BCL6 locus. All breakpoints were
located within the BCL6 major translocation cluster. In some cases, a
deletion in 3q leads to the loss of an 837-kb fragment extending from
the first intron of BCL6 to the third intron of the LPP gene. This de-
letion may bring the BCL6 gene under the control of regulatory ele-
ments of the LPP gene. DNA sequencing analysis of the junctional
sequences provided evidence that aberrant class switch recombina-
tion or somatic hypermutation may be involved in the generation
of BCL6 translocations [81]. In addition, in a more recent study, a
high LPP expression was associated with better treatment response of
patients with B-cell lymphomas. This improved clinical outcome was
possibly because of LPP-induced expression of genes responsible for
the increased differentiation of the leukemic B cells [83].
Another gene, which was found to be rearranged with LPP, is
MLL, the mixed lineage leukemia gene. MLL/LPP fusion transcripts
were detected in a patient with secondary leukemia (AML-M5, FAB
classification) after treatment with DNA topoisomerase II inhibitors.
Fluorescence in situ hybridization and Southern blot analyses identi-
fied a rearrangement in the MLL gene because of a novel t(3;11)
(q28;q23) chromosomal translocation in AML cells 3 years after che-
motherapy for a follicular lymphoma. Through inverse polymerase
chain reaction, the LPP gene on 3q28 was identified as the MLL fu-
sion partner. The predicted MLL/LPP fusion protein included the
AT hook motifs and methyltransferase domain of MLL joined to
the two last LIM domains of LPP. The reciprocal LPP/MLL tran-
script, predicted to include the proline-rich and leucine zipper mo-
tifs, and the first LIM domain of LPP were also detected by reverse
transcription–polymerase chain reaction. The new tumor-specific fu-
sion proteins MLL/LPP and LPP/MLL contain many features pre-
sent in other MLL rearrangements [84] (Figure 2) and, as such, could
be used as promising novel drug targets owing to their unique presence
in such tumors and absence in normal tissue. Interestingly, all these
tumor-specific fusion proteins, composed of AT hooks from other pro-
teins, are mainly localized within the nucleus [22] and possibly con-
tribute to altered LPP transcriptional targeting [63,64] (Figure 3B).
B) Overexpression of LPP Disrupts Normal LPP Signaling
LPP is highly upregulated by gains on 3q in squamous cell lung
carcinomas turning LPP into a potential candidate for pathogenesis
and diagnosis of lung cancer [85]. Amplification of the 3q region
accompanied by a 20-fold overexpression of LPP was detected in pri-
mary sarcomas and sarcoma cell lines pointing to an essential role of
LPP overexpression in tumorigenesis not only of epithelia but also of
tissues of mesenchymal origin [86].
LPP is a coregulatory binding partner for PEA3 [40]. PEA3 is a
member of an ETS domain transcription factor subfamily and regu-
lated by a number of signaling cascades including the MAPK path-
ways and Ras. PEA3 activates gene expression and is thought to play
an important role in promoting tumor metastasis [44,45]. LPP forms
a complex with PEA3 and is found to be associated with PEA3-
regulated promoters. By manipulating LPP levels, it is possible to
upregulate the transactivation capacity of PEA3 in a dose-dependent
manner [40]. Therefore, overexpression of LPP leads to an up-regulation
of PEA3 target genes. In a similar fashion, LPP can functionally in-
teract with the related PEA3 family member ER81. Thus, beyond
its own function as an independent transcription factor, LPP has
Figure 2. Schematic illustration of the HMGA2, LPP, and MLL proteins (upper panel) and the pathogenic fusion proteins found in human
neoplasia to date (lower panel). AT hooks (A) are specialized DNA-binding motifs, acidic domain (acidic), α-actinin binding site (αA), VASP
binding sites (V), nuclear export signal (N), LPP/TRIP6 similar region 1 (SR1), LPP/TRIP6 similar region 2 (SR2), zyxin/LPP/TRIP6/LIMD1
similar region (SR3), methyl-transferase–like domain (mld), PHD zinc fingers (Z), set domain (SET), and Scrib-binding motif (S).
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an additional nuclear function as a transcriptional coactivator [40]
(Table 1).
Among the PEA3 target genes are several MMPs [40]. Matrix
metalloproteinases in turn contribute to metastatic dissemination
of tumor cells by degrading the ECM, and their deregulated expres-
sion has been associated with the capability of tumor cells to metas-
tasize. In fact, PEA3 group genes are often overexpressed in different
types of cancer that also overexpress MMPs and that display a dis-
seminating phenotype [41,44,45].
Hence, it is tempting to speculate that overexpression of LPP
could cause an up-regulation of PEA3 targets such as MMPs result-
ing in an increased invasion and metastasis potential (Figure 3C ). In
support of this hypothesis, nonmetastatic breast cancer cells become
metastatic when PEA3 is ectopically overexpressed [44,45]. LPP
might be the link communicating changes in cytoskeleton or ECM
contacts associated with invasion and metastasis into PEA3-mediated
changes in gene expression profiles.
In comparison to LPP, zyxin overexpression has also been associ-
ated with increased invasiveness and migrational abilities of human
hepatocellular carcinoma cells [87]. However, zyxin gene transfer
into an Ewing sarcoma model resulted in the inhibition of tumor
growth accompanied by reconstitution of zyxin-rich focal adhesions,
reorganization of the actin cytoskeleton, and decreased cell motility
[88]. Thus, overexpression does not represent per se a consistent
mechanism for tumorigenesis but seems to depend on the cellu-
lar context.
C) LPP, an Abused Shuttle Protein
As LPP continually shuttles between the cell periphery and the
nucleus, it represents a potential novel link between cell surface
events and changes in gene expression [1]. LASP-1, another focal ad-
hesion protein, that is found to be overexpressed in human breast
and ovarian cancer, is known to interact with zyxin and LPP
[27,33,34,89]. Although LASP-1 has no classic nuclear import signal
of its own, it translocates into the nucleus. Therefore, it was specu-
lated that LASP-1 might bind to shuttle proteins such as zyxin and
LPP to use their transportation potential into the nucleus [2]. Hypo-
thetically, overexpression of LPP binding partners such as LASP-1 in
human neoplasia could interfere with normal LPP signaling, resulting
in an altered transcriptional signature of LPP that in turn could con-
tribute to tumorigenesis (Figure 3D). A summary of the putative
roles of LPP binding partners in human cancer is depicted in Table 2.
Conclusions and Future Prospects
In synopsis, it seems to be a common mechanism for tumors
showing a high rate of genetic instability to fuse protooncogenes such
Figure 3. Schematic illustration of the hypothetical, physiological (A), and pathological (C–D) LPP signaling in human neoplasia. (A) Phys-
iological LPP signaling: LPP permanently shuttles from cytosol into the nucleus and back, thereby transducing signals from the cell
surface to the transcription machinery and possibly vice versa. (B) Abnormal LPP signaling through formation of fusion proteins with
altered transcriptional signature. As an example, the most common fusion protein of the truncated HGMA2 with the LIM domains of LPP
is shown. (C) LPP overexpression leads to enhanced and possibly changed transcription of LPP target genes. (D) Overexpression of LPP
binding partners: overexpression of, for example, LASP-1 in tumor cells may lead to enhanced protein binding to LPP, increased nuclear
transportation of the shuttle partners, and potentially pathophysiological gene regulation.
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as HMGA2, MLL, and BCL6 with the LPP gene. These transloca-
tions lead to the formation of novel fusion gene products that are
highly specific for tumor cells, turning these fusion proteins into in-
teresting candidates for the rational design of specific antitumor medi-
cation. Furthermore, overexpression of LPP itself or its interacting
binding partners seems to be another mechanism for tumorigenesis
through interference with normal LPP signaling.
To date, there is an increasing line of evidence that LPP plays an
important role in the formation of a variety of human cancers. The
physiological role of LPP, however, remains largely unknown. Thus,
more work has to be undertaken to reveal the physiological function
of LPP and to delineate the functional differences between normal
and altered LPP signaling.
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